Low systemic exposure to tacrolimus correlates with acute rejection
- 1 February 1999
- journal article
- clinical trial
- Published by Elsevier BV in Transplantation Proceedings
- Vol. 31 (1-2), 296-298
- https://doi.org/10.1016/s0041-1345(98)01633-9
Abstract
No abstract availableThis publication has 12 references indexed in Scilit:
- Co-administration of Tacrolimus and Mycophenolate Mofetil in Cadaveric Renal Transplant RecipientsTransplantation Proceedings, 1998
- Pharmacokinetics of FK 506 and Mycophenolic Acid After the Administration of a FK 506–Based Regimen in Combination With Mycophenolate Mofetil in Kidney TransplantationTransplantation Proceedings, 1998
- MULTICENTER RANDOMIZED TRIAL COMPARING TACROLIMUS (FK506) AND CYCLOSPORINE IN THE PREVENTION OF RENAL ALLOGRAFT REJECTION1Transplantation, 1997
- A COMPARISON OF TACROLIMUS (FK506) AND CYCLOSPORINE FOR IMMUNOSUPPRESSION AFTER CADAVERIC RENAL TRANSPLANTATION1Transplantation, 1997
- A BLINDED, RANDOMIZED CLINICAL TRIAL OF MYCOPHENOLATE MOFETIL FOR THE PREVENTION OF ACUTE REJECTION IN CADAVERIC RENAL TRANSPLANTATION1Transplantation, 1996
- Consensus Document: Therapeutic Monitoring of Tacrolimus (FK-506)Therapeutic Drug Monitoring, 1995
- Therapeutic Drug Monitoring of Tacrolimus in Clinical TransplantationTherapeutic Drug Monitoring, 1995
- MYCOPHENOLATE MOFETIL FOR THE PREVENTION OF ACUTE REJECTION IN PRIMARY CADAVERIC RENAL ALLOGRAFT RECIPIENTSTransplantation, 1995
- Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejectionThe Lancet, 1995
- Bioavailability Improvement of Mycophenolic Acid Through Amino Ester DerivatizationPharmaceutical Research, 1990